U.S. Markets open in 5 hrs 56 mins

China Pharma Holdings, Inc. (CPHI)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.6000+0.0141 (+2.41%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5859
Open0.5888
Bid0.6001 x 2200
Ask0.6112 x 2200
Day's Range0.5855 - 0.6129
52 Week Range0.3500 - 1.6300
Volume120,836
Avg. Volume913,725
Market Cap26.148M
Beta (5Y Monthly)0.15
PE Ratio (TTM)N/A
EPS (TTM)-0.0670
Earnings DateMay 14, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
  • PR Newswire

    China Pharma Holdings, Inc. Reports Second Quarter 2021 Financial Results

    China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the financial results for the quarter ended June 30, 2021.

  • PR Newswire

    China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval

    China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its Candesartan hypertension product passed key bioequivalence tests. The Company plans to use the results of the key benchmark tests of consistency evaluation to apply for the National Medical Products Administration's (NMPA) approval. The NMPA is the Chinese agency for regulating drugs and medical devices (formerly the China Food and Drug Administr

  • PR Newswire

    China Pharma to Launch Highly Purified NMN+PQQ Product

    China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced plans to launch a highly purified NMN+PQQ product following the recent successful completion of a pilot scale test. β-Nicotinamide mononucleotide (NMN) is a derivative of the B-vitamin niacin, which is believed to significantly improve health and wellness.